Last 47 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 48.80 | 58.27 | 53.48 | 48.64 | 41.37 | 33.22 | 35.46 | 34.38 | 31.43 | 28.91 | 34.37 | 32.97 | 27.73 | 36.17 | 36.44 | 24.39 | 27.83 | 32.63 | 56.05 | 37.27 | 41.99 |
| — | +75.4% | +50.8% | +41.5% | +31.6% | +14.9% | +3.2% | +4.3% | +13.3% | -20.1% | -5.7% | +35.2% | -0.4% | +10.8% | -35.0% | -34.6% | -33.7% | -46.7% | -4.3% | -67.3% | -29.3% | |
| P/S Ratio | 13.02 | 15.03 | 14.09 | 13.80 | 10.79 | 9.40 | 8.62 | 9.07 | 8.77 | 7.82 | 7.97 | 8.66 | 8.56 | 9.41 | 8.06 | 6.01 | 7.08 | 8.43 | 11.52 | 12.29 | 9.70 |
| — | +59.9% | +63.4% | +52.2% | +23.1% | +20.2% | +8.2% | +4.7% | +2.4% | -17.0% | -1.2% | +44.2% | +20.9% | +11.7% | -30.0% | -51.1% | -27.0% | -10.5% | +31.8% | +47.3% | +11.9% | |
| P/B Ratio | 11.60 | 12.09 | 12.58 | 13.24 | 9.30 | 8.13 | 7.47 | 8.10 | 7.70 | 7.04 | 7.37 | 8.47 | 7.58 | 8.80 | 7.76 | 4.85 | 5.44 | 6.51 | 9.07 | 8.09 | 6.24 |
| — | +48.6% | +68.3% | +63.5% | +20.8% | +15.6% | +1.4% | -4.4% | +1.6% | -20.1% | -5.0% | +74.6% | +39.3% | +35.3% | -14.5% | -40.1% | -12.7% | +14.4% | +77.4% | +74.0% | +41.7% | |
| P/FCF | 63.54 | 53.43 | 39.27 | 57.55 | 39.12 | 38.96 | 282.99 | 59.98 | 31.48 | 26.10 | 41.19 | 46.10 | 148.14 | 48.43 | — | 34.79 | 28.06 | 88.09 | 141.66 | 45.81 | 33.52 |
| — | +37.1% | -86.1% | -4.1% | +24.3% | +49.3% | +587.1% | +30.1% | -78.8% | -46.1% | — | +32.5% | +427.8% | -45.0% | — | -24.1% | -16.3% | +224.8% | +35.1% | +53.7% | -38.6% | |
| EV / EBITDA | 36.47 | 43.05 | 38.43 | 38.96 | 29.74 | 24.19 | 27.68 | 27.15 | 24.69 | 21.99 | 26.02 | 25.95 | 21.35 | 27.37 | 27.38 | 21.16 | 17.86 | 20.33 | 37.01 | 37.49 | 26.81 |
| — | +78.0% | +38.9% | +43.5% | +20.5% | +10.0% | +6.4% | +4.6% | +15.6% | -19.7% | -5.0% | +22.6% | +19.5% | +34.6% | -26.0% | -43.5% | -33.4% | -43.7% | +13.7% | -37.6% | -46.2% | |
| EV / EBIT | 39.79 | 45.81 | 38.05 | 38.55 | 29.41 | 24.37 | 26.19 | 25.65 | 23.03 | 20.43 | 24.68 | 26.99 | 22.03 | 28.40 | 28.62 | 17.72 | 19.75 | 22.74 | 42.23 | 42.15 | 29.77 |
| — | +88.0% | +45.3% | +50.3% | +27.7% | +19.2% | +6.1% | -4.9% | +4.5% | -28.1% | -13.8% | +52.3% | +11.6% | +24.9% | -32.2% | -58.0% | -33.7% | -47.0% | +9.3% | -53.9% | -58.0% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.7% | 74.1% | 76.5% | 75.1% | 77.8% | 78.2% | 76.1% | 76.1% | 77.4% | 78.1% | 76.1% | 76.9% | 77.8% | 75.5% | 75.7% | 75.5% | 78.6% | 79.7% | 76.2% | 77.9% | 77.1% |
| — | -5.2% | +0.6% | -1.4% | +0.5% | +0.0% | +0.0% | -0.9% | -0.4% | +3.4% | +0.4% | +1.8% | -1.1% | -5.2% | -0.6% | -3.1% | +2.0% | +6.6% | -0.5% | +3.4% | +3.3% | |
| Operating Margin | 31.2% | 31.2% | 32.9% | 31.3% | 32.2% | 33.3% | 27.8% | 29.9% | 31.6% | 31.4% | 27.0% | 29.6% | 35.8% | 30.8% | 25.9% | 28.6% | 30.8% | 32.8% | 25.0% | 26.2% | 28.3% |
| — | -6.1% | +18.3% | +4.5% | +2.0% | +6.0% | +3.2% | +1.2% | -11.7% | +2.0% | +4.2% | +3.3% | +16.1% | -6.1% | +3.7% | +9.3% | +8.9% | +74.2% | +29.7% | +243.8% | +177.7% | |
| Net Margin | 26.8% | 25.5% | 26.5% | 28.4% | 26.3% | 28.3% | 24.0% | 26.5% | 27.6% | 27.3% | 23.5% | 26.0% | 30.7% | 25.9% | 22.0% | 24.7% | 25.6% | 25.5% | 20.2% | 32.8% | 23.6% |
| — | -9.9% | +10.2% | +6.9% | -4.5% | +3.5% | +2.2% | +2.0% | -10.3% | +5.5% | +6.8% | +5.2% | +20.1% | +1.7% | +9.0% | -24.6% | +8.2% | +70.1% | +34.3% | +339.6% | +69.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 24.8% | 5.2% | 6.0% | 6.7% | 5.8% | 6.3% | 5.3% | 6.0% | 6.2% | 6.3% | 5.6% | 6.2% | 7.1% | 6.3% | 4.9% | 5.1% | 5.1% | 5.0% | 3.7% | 5.6% | 3.9% |
| — | -16.8% | +13.7% | +10.4% | -6.5% | -0.4% | -5.5% | -2.8% | -12.3% | +0.4% | +13.6% | +21.4% | +39.7% | +24.2% | +33.7% | -7.9% | +30.2% | +119.7% | +65.7% | +432.4% | +115.0% | |
| ROA | 21.7% | 4.5% | 5.2% | 5.8% | 5.0% | 5.5% | 4.7% | 5.3% | 5.5% | 5.5% | 4.6% | 5.1% | 6.0% | 5.3% | 4.2% | 4.5% | 4.4% | 4.4% | 3.2% | 4.8% | 3.3% |
| — | -18.0% | +11.3% | +7.8% | -8.0% | +0.7% | +2.1% | +5.7% | -8.7% | +3.5% | +8.6% | +13.6% | +36.0% | +21.6% | +32.0% | -7.8% | +31.9% | +120.0% | +65.4% | +435.8% | +116.8% | |
| ROIC | 50.2% | 11.3% | 12.7% | 12.5% | 12.3% | 12.6% | 10.9% | 13.0% | 13.7% | 13.1% | 12.6% | 14.4% | 16.0% | 15.1% | 14.4% | 18.6% | 19.0% | 20.4% | 17.0% | 18.9% | 19.0% |
| — | -10.0% | +16.0% | -4.3% | -9.9% | -4.1% | -13.1% | -9.6% | -14.5% | -13.2% | -12.5% | -22.3% | -16.0% | -26.1% | -15.3% | -1.6% | +0.5% | +101.4% | +84.4% | +479.1% | +410.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 | 0.03 | 0.04 | 0.04 | 0.03 | 0.04 |
| — | — | — | — | — | — | -97.4% | -93.8% | -89.0% | -85.7% | -30.2% | -4.4% | -11.8% | -8.5% | -5.5% | -13.0% | -13.1% | -11.6% | -8.2% | -22.2% | -17.9% | |
| Debt / EBITDA | — | — | — | — | — | — | 0.01 | 0.03 | 0.04 | 0.06 | 0.39 | 0.38 | 0.35 | 0.44 | 0.56 | 0.62 | 0.50 | 0.50 | 0.69 | 0.71 | 0.74 |
| — | — | — | — | — | — | -97.3% | -93.2% | -87.5% | -85.4% | -30.5% | -38.5% | -29.3% | -13.3% | -18.6% | -12.8% | -33.0% | -57.8% | -45.3% | -74.1% | -70.1% | |
| Current Ratio | 7.98 | 9.46 | 7.13 | 7.98 | 6.64 | 8.78 | 8.87 | 8.84 | 9.21 | 9.87 | 9.44 | 4.65 | 9.13 | 8.71 | 9.07 | 9.06 | 12.83 | 11.16 | 10.48 | 11.18 | 11.33 |
| — | +7.8% | -19.6% | -9.8% | -28.0% | -11.0% | -6.0% | +89.9% | +1.0% | +13.2% | +4.0% | -48.6% | -28.8% | -21.9% | -13.5% | -18.9% | +13.2% | +2.4% | -25.5% | -13.8% | -14.3% | |
| Quick Ratio | 6.84 | 8.13 | 6.15 | 6.84 | 5.72 | 7.51 | 7.62 | 7.62 | 7.82 | 8.25 | 7.77 | 3.87 | 7.65 | 7.60 | 8.14 | 8.43 | 11.89 | 10.37 | 9.79 | 10.54 | 10.63 |
| — | +8.2% | -19.3% | -10.3% | -26.8% | -9.0% | -1.9% | +96.8% | +2.3% | +8.5% | -4.5% | -54.1% | -35.7% | -26.7% | -16.9% | -20.0% | +11.9% | +1.7% | -25.1% | -13.3% | -13.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IRMD stock.
IRadimed Corporation's current P/E is 48.8x. The average P/E over the last 4 quarters is 50.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
IRadimed Corporation's current operating margin is 31.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking IRadimed Corporation's business trajectory between earnings reports.